Qiagen Raises Guidance – Shares jump

Qiagen, a biotechnology firm, said 2Q adjusted EPS is expected to rise 68% on year at constant exchange rate to 0.55 - 0.56 dollar.

Charts (6)

Qiagen, a biotechnology firm, said 2Q adjusted EPS is expected to rise 68% on year at constant exchange rate to 0.55 - 0.56 dollar, compared with its prior guidance of at least 0.40 dollar, and net sales are estimated to grow 18% - 19% at constant exchange rates, compared with previous forecast of at least 12% growth.


From a chartist point of view, the stock price is trading above its upper Bollinger band thanks to the bullish gap opened this morning. Prices are supported by the rising 20- and 50-day simple moving averages. However, on a weekly chart, a rising wedge pattern is taking shape, calling for caution. Prices need to stand above 37.7E to maintain the bullish bias. Next resistance thresholds are set at 41E and 42.8E. Alternatively, a break below 37.7E would call for a reversal down trend with 34E as target.

Source: GAIN Capital, TradingView

Build your confidence risk free

More from Equities

Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.